Company Filing History:
Years Active: 2003
Title: Tzviel Sheskin: Innovator in Cannabinoid Research
Introduction
Tzviel Sheskin is a notable inventor based in Jerusalem, Israel. He has made significant contributions to the field of cannabinoid research, particularly through his innovative patent related to synthetic endogenous cannabinoids. His work has implications for various therapeutic applications, showcasing the potential of cannabinoid analogues in medicine.
Latest Patents
Tzviel Sheskin holds a patent for "Synthetic endogenous cannabinoids analogues and uses thereof." This invention relates to a compound of the general formula (I), which is a non-hydrolysable analogue of endogenous cannabinoids. These compounds have been found to be more potent therapeutic agents due to their stability against hydrolytic cleavage in the gastrointestinal tract. The cannabinoid analogues developed by Sheskin possess therapeutic value and can be utilized in pharmaceutical compositions for various medical conditions, including anti-inflammatory, anti-asthmatic, analgesic, hypotensive, antiemetic, and anti-spasmodic treatments. They may also be effective in treating and preventing glaucoma, migraines, and symptoms of multiple sclerosis.
Career Highlights
Tzviel Sheskin is associated with Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. His work at this esteemed institution has allowed him to explore the therapeutic potential of cannabinoids extensively. With a focus on developing stable and effective cannabinoid analogues, Sheskin has positioned himself as a key figure in cannabinoid research.
Collaborations
Throughout his career, Tzviel Sheskin has collaborated with prominent researchers in the field, including Raphael Mechoulam and Esther Fride. These collaborations have further enriched his research and contributed to advancements in cannabinoid science.
Conclusion
Tzviel Sheskin's innovative work in the field of synthetic cannabinoids highlights the potential for new therapeutic agents in medicine. His contributions are paving the way for future research and applications in cannabinoid therapy.